Vaxcyte (NASDAQ:PCVX) EVP Sells $1,561,320.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 18,000 shares of the firm’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $86.74, for a total transaction of $1,561,320.00. Following the sale, the executive vice president owned 145,435 shares in the company, valued at approximately $12,615,031.90. The trade was a 11.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Thursday, October 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.67, for a total transaction of $127,507.50.
• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The stock was sold at an average price of $59.52, for a total value of $79,399.68.
• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The shares were sold at an average price of $61.16, for a total value of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The shares were sold at an average price of $61.07, for a total value of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $53.86, for a total value of $121,185.00.

Vaxcyte Stock Up 0.4%

Shares of NASDAQ:PCVX traded up $0.26 during mid-day trading on Wednesday, reaching $66.96. 11,559,439 shares of the stock were exchanged, compared to its average volume of 1,556,494. The company has a market cap of $9.96 billion, a P/E ratio of -8.78 and a beta of 1.23. Vaxcyte, Inc. has a one year low of $39.87 and a one year high of $90.75. The stock’s 50 day simple moving average is $59.28 and its 200-day simple moving average is $56.40.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same period in the prior year, the firm posted ($1.22) earnings per share. Analysts anticipate that Vaxcyte, Inc. will post -8.07 EPS for the current fiscal year.

Vaxcyte News Summary

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Vaxcyte’s VAX-31 candidate delivered a positive Phase 3 result in the adult pneumococcal vaccine market. The late-stage win strengthens the case for VAX-31 and was viewed by some analysts as a potentially best-case outcome, improving confidence in the company’s path toward commercialization. Vaxcyte leaps on positive Phase III trial of VAX-31
• Positive Sentiment: Analyst support remains favorable. BTIG reaffirmed a Buy rating, while Needham assigned a $122 price target, substantially above recent trading levels. Additional VAX-31 data and other pipeline readouts are expected in the first half of 2027, providing potential future catalysts. BTIG Research Reaffirms Buy Rating for Vaxcyte
• Neutral Sentiment: Vaxcyte priced concurrent offerings totaling approximately $1 billion: about $500 million through common stock and pre-funded warrants at roughly $64 per share, plus $500 million of 1.50% convertible senior notes due 2032. The company can also sell additional securities underwriters’ over-allotment options. Proceeds should strengthen its balance sheet and fund VAX-31 development, manufacturing and other pipeline programs. Vaxcyte Announces Pricing of Concurrent Public Offerings
• Negative Sentiment: The equity component creates near-term dilution, while the convertible notes introduce potential future dilution if converted. The financing announcement overshadowed some of the clinical optimism and prompted a sharp retreat from the stock’s recent highs.
• Negative Sentiment: Unusually high put-option activity—8,093 contracts, reportedly 259% above typical volume—suggests increased hedging or bearish speculation, although options activity alone does not establish a fundamental change in Vaxcyte’s outlook.

Wall Street Analyst Weigh In

Several brokerages have issued reports on PCVX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday. Guggenheim increased their price objective on shares of Vaxcyte from $116.00 to $125.00 and gave the stock a “buy” rating in a research note on Monday. Needham & Company LLC raised their price objective on Vaxcyte from $110.00 to $122.00 and gave the company a “buy” rating in a report on Monday. Bank of America dropped their target price on Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a report on Monday, September 28th. Finally, Zacks Research raised Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Vaxcyte presently has a consensus rating of “Moderate Buy” and a consensus price target of $108.60.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds have recently bought and sold shares of PCVX. IFP Advisors Inc increased its position in Vaxcyte by 72.8% during the second quarter. IFP Advisors Inc now owns 560 shares of the company’s stock worth $33,000 after buying an additional 236 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its stake in Vaxcyte by 1,924.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 830 shares of the company’s stock valued at $38,000 after buying an additional 789 shares during the period. Capital Advisors Ltd. LLC acquired a new stake in shares of Vaxcyte in the first quarter valued at approximately $58,000. EverSource Wealth Advisors LLC boosted its stake in shares of Vaxcyte by 68.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,248 shares of the company’s stock worth $73,000 after acquiring an additional 507 shares during the period. Finally, Allworth Financial LP bought a new position in shares of Vaxcyte during the 2nd quarter worth approximately $75,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte’s lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.